Molecular mechanisms of adverse drug reactions

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 12, 2001, Pages 885-899

  Nelson, Sidney D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug structures; Drug toxicity; Metabolic activation

Indexed keywords

ANILIDE; ANILINE DERIVATIVE; AROMATIC COMPOUND; ARYLACETIC ACID DERIVATIVE; ARYLPROPIONIC ACID DERIVATIVE; DRUG; FATTY ACID DERIVATIVE; FELBAMATE; HALIDE; HERBACEOUS AGENT; HYDRAZIDE; HYDRAZINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TROGLITAZONE; UNCLASSIFIED DRUG;

CELL DAMAGE; CONFERENCE PAPER; DATA BASE; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOXICITY; HUMAN; MEDICAL LITERATURE; MEDLINE; PATHOGENESIS; PENNYROYAL; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035703703     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80093-X     Document Type: Conference Paper

References (81)

1. Reactive intermediates and their toxicological significance
2. Recent advances in drug metabolism and toxicity
3. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes
4. The role of metabolic activation in drug toxicity
5. Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals
6. Role of covalent and noncovalent interactions in cell toxicity: Effects on proteins
7. An immunochemical approach of identifying and characterizing protein targets of toxic reactive metabolites
8. Protein targets of xenobiotic reactive intermediates
9. Selective protein covalent binding and target organ toxicity
10. The immunologic and metabolic basis of drug hypersensitivities
11. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism?
12. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: Molecular mechanisms and pathology
13. Studies on the reactivity of acyl glucuronides-IV. Covalent binding of diflunisal to tissues of the rat
14. Cytochrome P4502C11 is a target of diclofenac covalent binding in rats
15. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia
16. Drug-protein conjugation and its immunological consequences
17. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions
18. Cytotoxicity of oxidative metabolites of procainamide
19. Sulfamethoxazole is metabolized to the hydroxylamine in humans
20. Autooxidative formation of a chemically reactive intermediate from amiodiaquine, a myelotoxin and hepatotoxin in man
21. Metabolic activation and drug toxicity
22. Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism
23. Metabolism of clozapine by neutrophils: Possible implications in clozapine-induced agranulocytosis
24. Mechanisms of formation and disposition of reactive metabolites that can cause acute liver injury
25. The role of metabolism in the hepatotoxicity of isoniazid and iproniazid
26. Hydralazine-induced lupus: Is there a toxic pathway?
27. Interactions of dihydralazine with cytochromes P4501A: A possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies
28. Metabolism of hydrazine anti-cancer agents
29. Free radical-mediated activation of hydrazine derivatives
30. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions
31. Adriamycin cardiomyopathy: Pathophysiology and prevention
32. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen
33. Worldwide activity and safety of bicalutamide: A summary review
34. Biochemical mechanisms in chemical induced lung injury: Roles of metabolic activation
35. Combined nitrofurantoin toxicity to liver and lung
36. Ticlid tablets
37. Abbott Zyflo (Zileuton) labelling recommends at least seven liver monitoring tests in first year on asthma therapy; leukotriene antagonist clears agency Dec. 9
38. Ticrynafen recall
39. Human anti-endoplasmic reticulum auto-antibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug
40. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: Comparison with two directly hepatotoxic drugs
41. Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity
42. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes
43. Wyeth Duract withdrawn after continued reactions to long-term use
44. Methoxyflurane metabolism and renal dysfunction: Clinical correlation in man
45. Biochemical and toxicological aspects of the volatile anesthetics
46. Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons
47. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration
48. Mutagenicity and organ damage of 1,2-dibromo-3-chloropropane (DBCP) and tris(2-3dibromopropyl) phosphate (TrisBP): Role of metabolic activation
49. Tianeptine - An instance of drug-induced hepatotoxicity predicted by prospective experimental studies
50. 4-VPA) and related branched chain carboxylic acids
51. The hepatotoxicity of valproic acid and its metabolites in rats. 1. Toxicologic, biochemical and histopathologic studies
52. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not anticonvulsant effect
53. Mechanisms of chemical carcinogenesis: Nature of proximate carcinogens and interactions with macromolecules
54. Possible mechanism of liver necrosis caused by aromatic organic compounds
55. Metabolic activation of drugs to toxic substances
56. Specific targets of covalent drugs-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury
57. A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes
58. Inhibition of carbamyl phosphate synthetase-1 and glutamine synthetase by hepatotoxic doses of acetaminophen in mice
59. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by a reactive metabolite of acetaminophen and mass spectral characterization of an arylated active site peptide
60. Acetaminophen binds to mouse hepatic and renal DNA in human therapeutic doses
61. Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry
62. Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac
63. Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: Possible role in allergic reactions
64. Modulation to macrophage functioning abrogates the acute hepatotoxicity of acetaminophen
65. Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice
66. Mechanisms of inflammatory liver injury: Adhesion molecules and cytotoxicity of neutrophils
67. Acetaminophen elimination-kinetics in neonates, children, and adults
68. The effects of age and glutathione depletion on hepatic glutathione turnover in vivo determined by acetaminophen probe analysis
69. Acetaminophen overdose in young children. Treatment and effects of alcohol and other additional ingestants in 417 cases
70. The safety of acetaminophen and ibuprofen among children younger than two years old
71. Therapeutic misadventures with acetaminophen: Hepatotoxicity after multiple doses in children
72. Unintentional acetaminophen ingestion in children and the potential for hepatotoxicity
73. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants
74. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature
75. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission